<?xml version="1.0" encoding="UTF-8"?>
<p>The breakthrough in ANXA1 signaling exogenously was shown when ANXA1 and its derived peptide (Ac2-26) were able to reduce the transmigration of neutrophils across endothelial cell monolayers, which was blocked by an FPR antagonist (
 <xref rid="B84" ref-type="bibr">Walther et al., 2000</xref>). After which, several studies have demonstrated that the anti-inflammatory actions of secreted ANXA1 work via FPR1 and FPR2/ALXR (
 <xref rid="B80" ref-type="bibr">Sugimoto et al., 2016</xref>). These receptors can homodimerize or heterodimerize to cause different cellular responses when bound to ANXA1. For instance, ANXA1 and its peptides can activate the p38 MAPK pathway via homodimerized FPR2 receptor (
 <xref rid="B27" ref-type="bibr">Filep, 2013</xref>). However, stimulation of heterodimerized FPR1/FPR2 by ANXA1 peptides results in PMN apoptosis through the activation of caspase 3 (
 <xref rid="B27" ref-type="bibr">Filep, 2013</xref>). Notably, ANXA1, through FPR1, promotes epithelial wound repair through the activation of NADPH oxidase (NOX1) (
 <xref rid="B40" ref-type="bibr">Leoni et al., 2013</xref>). Further, ANXA1 activation of FPR2 results in ERK phosphorylation (
 <xref rid="B7" ref-type="bibr">Bena et al., 2012</xref>) and NF-ÎºB activation (
 <xref rid="B35" ref-type="bibr">Jia et al., 2013</xref>).
</p>
